Navigation Links
Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
Date:12/7/2010

MOUNTAIN VIEW, Calif., Dec. 7, 2010 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration (FDA) in December to discuss the Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for AZ-004 (Staccato loxapine).  Alexza has submitted an Information Package to the FDA in preparation for the meeting, with the responses or proposals to the issues raised in the CRL.  AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

The Company anticipates the FDA meeting will be a comprehensive review of the issues identified by the FDA in the CRL, and Alexza's planned responses to those issues.  The Company's primary meeting goal is to clarify and fully understand the key issues, and to establish a plan to respond to those issues.  While the CRL follow-up meeting will be held in December, the Company does not expect the official FDA meeting minutes to be available until at least late January 2011.  The Company anticipates providing a further U.S. regulatory update on AZ-004 after receipt of the official FDA correspondence.

Alexza also announced today that it has met with the European Medicines Agency (EMA) and has received written confirmation that AZ-004 is eligible for submission of a Marketing Authorization Application (MAA) under the centralized registration procedure.  In addition, Alexza has been notified of the Rapporteur and Co-Rapporteur appointments for the AZ-004 review.  The Company believes that the comprehensive clinical development program for AZ-004 meets the requirements for the MAA filing.  Alexza expects to submit the MAA mid-year 2011.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... 7 Ardea,Biosciences, Inc. (Nasdaq: RDEA ) ... activity of the Company,s non-nucleoside reverse,transcriptase inhibitor (NNRTI) ... known causative agent of AIDS,including NNRTI-resistant strains., ... Conference on Retroviruses,and Opportunistic Infections (CROI) in Boston., ...
... gastrointestinal and lipid effects between ... N.J., Feb. 6 Bristol-Myers Squibb,Company (NYSE: ... study, in which,300 mg of once-daily REYATAZ(R) (atazanavir ... similar antiviral efficacy to twice-daily,lopinavir 400 mg and ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce that ... at North Carolina State’s College of Veterinary Medicine has ... for Distinguished Volunteer Service—the organization’s highest award. , ... volunteer experts to direct its work to improve the ...
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... prevent the rejection of newly transplanted organs and ... entire immune systems. Such potentially life-saving treatments can, ... infections. , Now researchers at the University ... Medicine and the UNC Lineberger Comprehensive Cancer Center ...
... RICHMOND, Va., Feb. 11 Access to high quality ... healthy newborns. In the Philippines, six new birthing centers ... for women in Pili, Camarines Sur. "We want to ... care facilities, which is the most important factor in ...
... Abbott ( NYSE: ABT ),today announced it received ... (FDA) for its new, compact hematology instrument, CELL-DYN,Emerald(TM). ... hematology,platform by offering a high performance, affordable solution ... As small to mid-sized hospital ...
... is to have compassion for others , , WEDNESDAY, Feb. 11 ... person,s ability to empathize with others, suggests a U.S. study ... a sound played in a specific cage as negative by ... that cage. But a genetically different strain of mice that ...
... Feb. 11 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... its financials through the first nine months of 2008 ... Revenues generated through the nine-months of 2008 amounted to ... 2007. The Company substantially lowered its General and Administrative ...
... U.S. Surgeon General Kenneth P. Moritsugu urged members of ... nutrition knowledge and patient-care skills to prevent diseases such ... that exist in the United States and to educate ... well-being.Moritsugu, who was Deputy Surgeon General from 1998 to ...
Cached Medicine News:Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:Philippine Birthing Centers Help New Mothers, Healthy Infants 2Health News:Philippine Birthing Centers Help New Mothers, Healthy Infants 3Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:Empathy Might Be in the Genes 2Health News:Solos Endoscopy, Inc. Posts First Nine Months Financials for 2008 on Pinksheets.com 2Health News:Registered Dietitians Can Do Much to Help Educate Americans and Eliminate Health Disparities in U.S., Says Former Surgeon General 2Health News:Registered Dietitians Can Do Much to Help Educate Americans and Eliminate Health Disparities in U.S., Says Former Surgeon General 3
Inquire...
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: